Merck or CVS: Only One Gets My Dividend Dollars for the Next 10 Years

Gian Estrada • 5 minute read
Reviewed by: David Hanson
Last updated Nov 15, 2026

Pressmaster from Pressmaster and Ri_Ya from pixabay

Key Takeaways

  • Merck raised its dividend 5.1% in fiscal 2025 and yields 2.3%; CVS Health yields 3.0% but hasn’t raised since 2023.
  • CVS’s dividend uses 22% of trailing free cash flow, against 57% at Merck.
  • CVS expects to finish its split in the first half of 2028, the year Keytruda’s main U.S. patent expires.
  • With no raises, CVS still out-pays Merck by about $69 over 10 years, though Merck’s yearly check passes it in year seven.

On Nov. 4, CVS Health (CVS) raised its outlook and announced a plan to split into two public companies by the first half of 2028. The stock fell 12.5% that day, then won back most of it.

Six days earlier, Merck (MRK) posted a beat-and-raise quarter. But Keytruda, its biggest drug, loses its main U.S. patent in 2028 too.

If I can only own one for the next decade of dividends, which gets the money?

MetricMerck (MRK)CVS Health (CVS)
Dividend yield2.3%3.0%
Annual dividend$3.40 a share$2.66 a share
Dividend growth, fiscal 2020-20255.8% a year5.9% a year
Dividend growth, fiscal 20255.1%None
Cash dividend payout ratio (TTM)57% 22%
Net debt/EBITDA1.5x3.0x

Yields at Nov. 13, 2026 closing prices; payout ratios to Sept. 30, 2026, from company filings.

6 Safe Dividend Stocks Paying Retirees 6%+ Yields

There are over 100 stocks paying 6%+ annual dividends today.

But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.

They’re all yours for free as part of our new investment report, which you can access right here.

Merck’s Dividend Is Still Climbing

Third-quarter sales rose 5% to $18.1 billion, and CFO Caroline Litchfield said on the call, “We remain committed to the dividend with the goal of increasing it over time.”

The dividend took a manageable 57% of free cash flow in the year to Sept. 30, but the cash swings:

Bar chart from TIKR of Merck's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
MRK Free Cash Flow and Common Dividends Paid: 2016-2025 (TIKR)

Free cash flow fell short of it in fiscal 2017 and fiscal 2020.

The near-term risk: a Dutch court’s Oct. 7 injunction in a Halozyme Therapeutics patent fight halted sales of subcutaneous Keytruda in Denmark and Italy and blocked launches in four other European countries. Intravenous Keytruda isn’t affected.

CVS’s Cash Is Bouncing Back

CVS pays the bigger check, and on Nov. 4 it raised its cash flow from operations guidance to at least $15.5 billion, from at least $11.5 billion.

Free cash flow had fallen from $15.8 billion in fiscal 2021 to $6.33 billion in fiscal 2024 while dividend payments kept rising:

Bar chart from TIKR of CVS Health's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
CVS Free Cash Flow and Common Dividends Paid: 2016-2025 (TIKR)

The payout ratio dropped from 53.3% in fiscal 2024 to 22% in the year to Sept. 30, partly on what CFO Brian Newman called “the timing of certain payments.”

CVS isn’t spending that room on the dividend; it’s restarting buybacks this quarter. It says both post-split companies should “pay an attractive dividend,” without saying how today’s $2.66 a share gets divided.

Why CVS Still Gets My Dividend Dollars

CVS gets my money, barely.

On $10,000 at Nov. 13 closes, CVS pays about $298 a year and Merck $230. If CVS’s dividend stays flat and Merck’s grows 5.1% a year, CVS pays about $69 more over 10 years. At both five-year growth rates, it’s about $902.

A frozen CVS still wins, and any raise widens the lead.

Merck’s case is real: it’s still raising, carries half CVS’s leverage, and once this year’s $6.05 a share of deal charges roll off, consensus has normalized EPS back at $8.98 in fiscal 2027, level with fiscal 2025:

Bar chart from TIKR of Merck's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
MRK Normalized EPS, Actual and Consensus Estimates: 2023-2028 (TIKR)

Two things could flip it: a big Merck raise (its last came on Nov. 18, 2025, so another decision is close), or a small post-split dividend from either CVS company.

Forget CVS Health: 6 Safe 6%+ Dividend Yields You Can Buy Right Now

Dividends can hold the key to enormous wealth. But only if you buy the right ones.

Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.

We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And CVS Health isn’t one of them.)

Learn more here.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required